Preparation method of tissue engineering cornea

Abstract

The invention belongs to the technical field of tissue engineering and provides a preparation method of a tissue engineering cornea. A support material prepared from human corneal limbal cell compound animal source cornea is adopted, a bowman membrane, a substrate layer and a descemet membrane are separated and are coated with cell suspension prepared from human corneal limbal cells, and then crosslinking and bonding are carried out, so that construction of a cell-containing tissue engineering cornea is completed, and the tissue engineering cornea prepared by adopting the preparation method has the advantages of high tissue compatibility and industrialization; besides, the adopted cells are not subjected to in-vitro multiplication culture, cell characters are stable, differentiation is hardly caused, and the safety of the tissue engineering cornea is guaranteed.

Description

Technical field [0001] The present invention is an organizational engineering technology field, which involves a method of building corneal corneal. Background technique [0002] A cornea is one of the tissues that maintain the normal vision of the human body. The vision loss or blindness caused by the acute damage, perforation, ulcer, and lesions of the cornea, and even the eyeball removal, which has a great impact on the patient's normal life and psychological psychology. [0003] Nowadays, corneal blindness has become the second general blind disease in the world. The most effective method for treating corneal blindness is corneal transplantation. However, the lack of corneal sources, which causes patients to be treated in a timely manner and blind.According to statistics, about 4 million corneal blind patients in my country need corneal transplantation, but less than ten cases of patients have corneal transplantation.The lack of corneal supply sources restricts the treatment ...

AI Technical Summary

Problems solved by technology

[0006] The current existing technology shows (such as Chinese patents 201410264542.X and 201410230365.3) that the artificial cornea prepared only provides scaffold materials and lacks seed cells with active functions. When it is implanted in the body for repair, it only relies on the repair ability of the patient's affected cells. Damage repair prolongs the treatment process, but also increases the probability of repair failure. At the same time, the scaffold material prepared by it is an exogenous material, which has poor compatibility with the patient's tissue after implantation, and there is a risk of rejection

[0007] Chinese patent 03140113.9 discloses an artificial tissue engineered biocornea, using epithelial and endothelial cells as seed cells, but the carrier used is animal tissue or allogeneic corneal components, which retains foreign aid cells or cell residual components, and does not The residual components are controlled and described, which will cause immune rejection and virus cross-infection in the human body, resulting in rejection of the implant by the patient after implantation and repair, resulting in treatment failure. At the same time, the seed cells used do not have differentiation pluripotency. The limitation of the therapeutic effect. At the same time, this kind of method needs to expand the cells by in vitro culture, which changes the living environment of the cells and increases the possibility of cell mutation. At the same time, the cell culture process is long, which delays the treatment process. , and may face a second operation, bringing potential harm to the patient's health

Images